Icon buys Veeda’s UK biomarker lab

By Antoine Clarke

- Last updated on GMT

Related tags: Laboratory

The Oxford, UK, biomarker laboratory facilities of India’s Veeda CR have been taken over by Icon Development Solutions, in a deal which both consolidates existing customer relationships for the buyer and opens up new product areas to focus on.

The Veeda deal adds biomarker analysis and development capacity to Icon’s offering which, the firm hopes, will help it attract development work from sponsors keen to make no/go development decisions a the earliest possible stage.

John Chapel, who headed Veeda Laboratories’ Oxford facility, told Outsourcing-pharma, that the timing for the move was straightforward: “Veeda wanted to sell and Icon wanted to buy,”​ he said.

Veeda Labs provides specialist laboratory services to many of the global pharmaceutical and biotechnology drugmakers. Icon already has a UK research centre at Manchester, and the firm acquired Prevalere Life Sciences, a USA-based bioanalytical and immunoassay laboratory, in November 2008.

Thomas Frey, President, Icon Development Solutions, highlighted Veeda’s “very strong reputation for biomarker development​” and “well-established relationships with top-tier pharmaceutical and biotechnology companies​.”

He went on to say that the new unit’s research team will “greatly enhance Icon’s existing team of biomarker experts​.”

A call to the Oxford site confirmed that the deal has been completed, although some details of how the new site will fit into Icon’s management structure have not been announced.

Biomarker analysis

Use of biomarker analysis by drug developers has increased considerably in recent years. The technique provides a way of assessing the impact of a particular drug or candidate on a disease state via analysis of pre-characterised markers.

This approach allows no/go development decisions to be taken at an early stage, helping researchers identify promising projects and, perhaps more crucially, halt the development of ineffectual drugs at the earliest possible stage.

Related news

Show more

Related products

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Related suppliers

Follow us

Products

View more

Webinars